Annual Report of Financial Year 2025-26

Date: 24th August, 2026 BSE Limited, 25th Floor, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 531569 Sub.: Submission of Annual Report of the Company under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we are submitting herewith the Annual Report of the Company along with the Notice of AGM for the financial year 2025-2026. The same is also available on the website of the Company at www.sanjivani.co.in . Thanking you, Yours faithfully, For Sanjivani Paranteral Limited Ravikumar Bogham Company Secretary Cum Compliance Officer ANNUAL REPORT 2025-26 Performance. Progress. Purpose. SShhaarreedd SSttrroonnggeerr SSuussttaaiinnaabbllee SSuucccceessss PPeerrffoorrmmaannccee GGrroowwtthh Committed to EExxcceelllleennccee........ Annual Report 2025-26 2 PPrrooggrreessss TThhrroouugghh IInnnnoovvaattiioonn EExxcceelllleennccee iinn CCaarree FY26 was a defining year for Sanjivani Paranteral Limited — one where resilience met opportunity and our growth engines began converging into a stronger enterprise. Building on the momentum of previous years, we entered Fy26 with a renewed vision: to broaden our horizons, deepen our impact and enhance patient care across global markets. During the year, we strengthened our base business through portfolio expansion, product launches and deeper penetration into key geographies, while simultaneously laying the groundwork for the next phase of growth through our strategic joint ventures. We expanded our presence across Latin America, Central America, the Middle East and Francophone Africa, supported by new regulatory approvals and filings. These initiatives reinforce our position as a trusted global partner in life-saving medicines while staying rooted in our core purpose of delivering high-quality, patient-centric solutions that create lasting value. FY27 is poised to be a pivotal year. For the first time, all three growth engines — the base business, the SPL Infusion Pvt. Ltd. for IV infusions, and the Alevia Healthcare S.R.O. for nutraceuticals — will contribute simultaneously. This confluence is set to drive scale, diversification and resilience. At Sanjivani, expanding horizons is not just about growth; it is about creating enduring healthcare impact and sustainable access to quality medicines — while consistently delivering value to stakeholders. Annual Report 2025-26 3 TABLE OF CONTENTS Corporate Overview Manufacturing Plants 06 About Us 07 Vision, Mission & Values 08 Long-Term Growth Drivers 09 Key Financial Highlights 10 Revenue Mix 12 Global Footprint 13 Product Portfolio 14 CDMO Clients 15 Board of Directors 16 Chairman’s Communique 17 Statutory Reports Board’s Report 20 Annexure I - Management Discussion And Analysis 29 Annexure II - Director Report 34 Annexure III - Secretarial Audit Report 35 Annexure IV - Conservation of Energy 39 Annexure V - CSR Activites 40 Financial Statements Independent Auditor’s Report (Standlone) 55 Standalone Financial Statements 64 Independent Auditor’s Report (Consolidated) 96 Consolidated Financial Statements 102 Notice 135 Annual Report 2025-26 4 Corporate Overview I Statutory Reports I Financial Statements CORPORATE INFORMATION Board of Directors Mr. Ashwani Khemka Registered Office Executive Director – Chairman & 205, P.N. Kothari Industrial Estate, Managing Director L.B.S Marg, Bhandup (West), DIN: 00337118 Mumbai – 400078 Mr. Srivardhan Khemka Executive Director DIN: 08942106 Mr. Basant Shrivastava Corporate Office Non-Executive - Independent Director 1404, B-Wing, O2 Business Commercial Park, DIN: 02581255 (Appointed w.e.f 11th Sep. 2025) Asha Nagar Park Road, Opp. Asha Nagar, Mulund (West), Mumbai - 400080 Mrs. Mrunmai Sarvankar Non-Executive - Independent Director DIN: 07173011 (Term Expired on 19 Sep. 2025) Mrs. Monika Singhania Bankers Non-Executive - Independent Director DIN: 07950196 ICICI Bank Limited Kotak Mahindra Bank Mr. Abhay Shah Non - Executive Independent Director DIN: 10562812 Chief Financial Officer Company Secretary & Compliance Officer Mr. Pritesh Jain Mr. Ravikumar Bogham Statutory Auditors Secretarial Auditors R.B. Gohil & Co. HD AND ASSOCIATES Chartered Accountant Office Number 411, Parikh Market Building, 1st Floor, K.P. Shah House-1, K.V. Road, Jamnagar, Opera House, Mumbai - 400004 Jamnagar-361001 Factories UUnniitt 11 Unit 2 PPlloott NNoo.. RR--4400,, Plot No. 323/1, Central Hope Town, TTTTCC IInndduussttrriiaall AArreeaa,, RRaabbaallee,, Camp Road, Selaqui, NNaavvii MMuummbbaaii –– 440000770011 Dehradun – 248197, Uttarakhand Annual Report 2025-26 5 Corporate Overview I Statutory Reports I Financial Statements MANUFACTURING PLANTS Alevia Healthcare S.R.O., Czech Republic SPL Infusion Private Limited, Pune Annual Report 2025-26 6 Corporate Overview I Statutory Reports I Financial Statements ABOUT US Sanjivani Paranteral is a WHO GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables, IV fluids and oral solids with an extensive experience spanning more than three decades. Our company primarily focuses on life-saving drugs and exports to over 25 countries. Your Company is headquartered in Mumbai with WHO GMP certified manufacturing facility in Navi Mumbai and Dehradun. Your Company caters to major therapeutic areas encompassing central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, anti-allergic, supported by a robust R&D setup. 4 25 Countries Manufacturing Facilities Geographical Reach 25+ years ~70% Experience Exports Revenue 60 million 720 million IV Fluid Bottles Annual Tablet Capacity 84 million 12 million Annual Ampoules Capacity Annual Liquid injectables Capacity 120 million 180 million Annual B Lactam Tablet Capacity Annual B Lactam Capsule Capacity 72 million 48 million Annual Capsule Capacity Annual Vial Capacity Annual Report 2025-26 7 Corporate Overview I Statutory Reports I Financial Statements VISION, MISSION & VALUES Vision of the Company VISION To be one of India’s best research-based pharmaceutical companies, through focus on quality and customer satisfaction To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members To grow the company on the foundation of Passion, Performance & Partnership MISSION Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities VALUES 1. Quality Products that we are proud of 2. Customer Satisfaction Exceeding Customer expectations 3. Growth for all stakeholders Exceeding Customer expectations 4. Professionalism A culture of innovative thinking, backed by disciplined execution Annual Report 2025-26 8 Corporate Overview I Statutory Reports I Financial Statements LONG-TERM GROWTH DRIVERS Expand Product Portfolio Strategic Partnerships & Collaborations Expand into New Geographies Therapeutic Diversification Annual Report 2025-26 9 Corporate Overview I Statutory Reports I Financial Statements KEY FINANCIAL HIGHLIGHTS FOR THE YEAR Revenue from EBITDA Margin Operations 648 16.4% New Geographies PAT Margin Added during the 10.7% Year 4 Domestic & Export Total (share in revenue) Products 179 21.5% & 78.5% Annual Report 2025-26 10 Corporate Overview I Statutory Reports I Financial Statements KEY FINANCIAL HIGHLIGHTS REVENUE EBITDA 648 106 26 26 PAT No. of Products 69 179 26 26 Annual Report 2025-26 11 Corporate Overview I Statutory Reports I Financial Statements REVENUE MIX Product Mix FY26 FY25 53.45% 43.10% 3.45% Geographical Mix Geographical Mix FY26 FY25 78.50% 21.50% Region Mix Region Mix FY26 FY25 41.68% 22.99% 32.72% 2.61% Annual Report 2025-26 12 Corporate Overview I Statutory Reports I Financial Statements GLO [Showing first 8,000 characters — download PDF for full document]